Skip to main content
Equibles
CATX logo

CATX · Perspective Therapeutics, Inc.

Track CATX — free

Use CATX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about CATX

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$3.22 +0.02 (+0.63%) At close · Aug 17
Market Cap
$370.99M
Shares
114.15M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.22 Open$3.21 Day$3.20–3.31 52W close$2.05–5.65 Avg vol 30d1.4M Short int23.5M · 20.6% float · 25.7d Short vol62% Last earningsJan 13, 2025 DataJun 2024–Aug 2026 Filing10-Q · Aug 10

Raw chart and full-history price indicators begin at the captured split on Jun 17, 2024; bars on opposite sides are not compared.

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 10, 2026

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Buy Momentum Neutral Sentiment Bearish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 14.3 · calm Equity put/call 0.52
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg −8%
below
Price vs 50-day avg +5%
above
RSI (14) 56
neutral
MACD trend Positive
52-week position 33%
mid-range
Momentum
relative strength
Neutral
1-month return +10%
trailing
6-month return −41%
trailing
YTD return +17%
this year
Relative strength −54%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow Distributing
-9% holders QoQ · +23 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
20.56% of float · ▲ +3.0% MoM · 25.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
126 holders — mid 3-yr range
Squeeze score 81
high risk · 0–100
Fundamentals
Strong
Revenue growth +24%
Y/Y
Gross margin 24%
expanding
EPS growth −14%
Y/Y
Free cash flow $-95.2M
Balance sheet $29.0M
net cash
Quant / Vol
risk profile
Very High
Volatility 109%
annualized · 1-yr
Max drawdown −59%
past year
ATR 5.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−8% Bearish
Price vs 50-day avg
+5% Bullish
RSI (14)
56 Neutral
MACD trend
Positive Bullish
52-week position
33% Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow Distributing
-9% holders QoQ · +23 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
20.56% of float · ▲ +3.0% MoM · 25.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
126 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2 Now $3 · 33% Range high $6
vs 200-day avg -8% vs 50-day avg +5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
patients enrolled with lapemelanotide zapixetar (VMT01) 27 as of July 31, 2026 —
patients treated with bamzireotide navoxetan (VMT-α-NET) 76 as of July 31, 2026 —
patients treated with PSV359 17 as of July 31, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CATX
Perspective Therapeutics, Inc.
this stock
$370.99M +17.1% — — 20.6%
ABT
Abbott Laboratories
 $193.78B -11.9% +5.7% 31.2 1.3%
SYK
Stryker Corp
 $130.11B -3.5% +11.2% 35.2 2.2%
MDT
Medtronic plc
 $116.83B -5.0% +8.4% 24.5 1.4%
BSX
Boston Scientific Corp
 $74.64B -46.1% +12.5% 20.9 1.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
126
% held
76.2%
Net QoQ
+6.8M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
111
View
Short & Settlement
Short Interest Rising
Shares short
23.5M
Days to cover
25.7d
Change
+689.4K sh
View
Short Volume
Short vol %
62%
As of
Aug 17, 2026
Short Total
View
Fails to Deliver
FTD shares
12.3K
Value
$36.4K
As of
Jul 17, 2026
View
Off-Exchange
Off-exchange %
43.3%
Week of
Jul 13, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$5.9M
Net income (FY)
$-103.1M
EPS diluted
$-1.40
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 10, 2026
This year
20
View
Proposed Sales
Value
$39.5K
Shares
2.5K
Filed
Sep 12, 2024
View
Exempt Offerings
Offering
$87.4M
Filed
Mar 18, 2024
View
Earnings & Events
Earnings Calls
Last call
Jan 13, 2025
View

Performance

Raw-price comparisons begin at the captured split on Jun 17, 2024; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
CATX +7.3% +10.3% -40.6% +10.7% +17.1%
SPY +0.4% +4.5% +13.8% +3.9% +13.9%
vs SPY +6.9% +5.8% -54.4% +6.7% +3.2%
Key facts CIK 728387 CUSIP 46489V302 13F (30d) 126 filings 122 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)